Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182

NCT02500121 is registered in ClinicalTrials.gov with Matthew Galsky as lead sponsor.

NCT NCT02500121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02500121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Lead sponsor
Matthew Galsky
Phase
Phase 2
Overall status
Completed
Start date
November 11, 2015
Completion date
January 1, 2021
Enrollment
108 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, urothelial carcinoma